Elevated Lipoprotein(a) Levels and Atrial Fibrillation: A Systematic Review
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective: The role of lipoprotein(a) (Lp[a]) as a possibly causal risk factor for atherosclerotic cardiovascular disease has been well established. However, the clinical evidence regarding the association between Lp(a) levels and atrial fibrillation (AF) remains limited and inconsistent. This study aimed to analyze the association between elevated Lp(a) levels or single-nucleotide polymorphisms (SNPs) related to high levels of Lp(a) and AF. Methods: This systematic review was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. A literature search was performed to identify studies that evaluated the association between Lp(a) levels or SNPs related to high levels of Lp(a) and AF. Observational studies with a cross-sectional, case-control, or cohort design were included in this systematic review, without limitations according to language, country, or publication type. Results: Eleven observational studies including 1,246,817 patients were eligible for this systematic review. Two cross-sectional studies, 5 prospective/retrospective cohort studies, and 4 Mendelian randomization studies were analyzed. Two cross-sectional studies that compared Lp(a) levels between patients with and without AF showed conflicting results. Cohort studies that evaluated the incidence of AF according to Lp(a) levels showed different results: no association (3 studies), a positive association (1 study), and an inverse relationship (1 study). Finally, Mendelian randomization studies also showed heterogeneous results (positive association: 2 studies; inverse association: 1 study; no association: 1 study). Conclusion: Although there could be an association between Lp(a) levels and AF, the results of the studies published to date are contradictory and not yet definitive. Therefore, further research should clarify this issue.
Abstract
Objective: The role of lipoprotein(a) (Lp[a]) as a possibly causal risk factor for atherosclerotic cardiovascular disease has been well established. However, the clinical evidence regarding the association between Lp(a) levels and atrial fibrillation (AF) remains limited and inconsistent. This study aimed to analyze the association between elevated Lp(a) levels or single-nucleotide polymorphisms (SNPs) related to high levels of Lp(a) and AF. Methods: This systematic review was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. A literature search was performed to identify studies that evaluated the association between Lp(a) levels or SNPs related to high levels of Lp(a) and AF. Observational studies with a cross-sectional, case-control, or cohort design were included in this systematic review, without limitations according to language, country, or publication type. Results: Eleven observational studies including 1,246,817 patients were eligible for this systematic review. Two cross-sectional studies, 5 prospective/retrospective cohort studies, and 4 Mendelian randomization studies were analyzed. Two cross-sectional studies that compared Lp(a) levels between patients with and without AF showed conflicting results. Cohort studies that evaluated the incidence of AF according to Lp(a) levels showed different results: no association (3 studies), a positive association (1 study), and an inverse relationship (1 study). Finally, Mendelian randomization studies also showed heterogeneous results (positive association: 2 studies; inverse association: 1 study; no association: 1 study). Conclusion: Although there could be an association between Lp(a) levels and AF, the results of the studies published to date are contradictory and not yet definitive. Therefore, further research should clarify this issue.
참고문헌 (34)
- Zakeri R, "The burden of proof : the current state of atrial fibrillation prevention and treatment trials", Heart Rhythm, 14, pp.763~782 (2017)
- Kornej J, "Atrial fibrillation : global burdens and global opportunities", Heart, 107, pp.516~518 (2021)
- Sgreccia D, "Comparing outcomes in asymptomatic and symptomatic atrial fibrillation : a systematic review and meta-analysis of 81, 462 patients", J Clin Med, 10, pp.3979~ (2021)
- Shin J, "Risk factors associated with atrial fibrillation in elderly patients", J Clin Med Res, 15, pp.148~160 (2023)
- Odeh A, "Interrelationship between inflammatory biomarkers and collagen remodeling proteins in atrial fibrillation", Clin Appl Thromb Hemost, 29, pp.10760296231165055~ (2023)
- Huxley RR, "Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors : the Atherosclerosis Risk in Communities(ARIC)study", Circulation, 123, pp.1501~1508 (2011)
- Guan B, "Blood lipid profiles and risk of atrial fibrillation : a systematic review and meta-analysis of cohort studies", J Clin Lipidol, 14, pp.133~142 (2020)
- Bhatia HS, "Lipoprotein(a) : evidence for role as a causal risk factor in cardiovascular disease and emerging therapies", J Clin Med, 11, pp.6040~ (2022)
- Reyes-Soffer G, "Lipoprotein(a) : a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease : a scientific statement from the American Heart Association", Arterioscler Thromb Vasc Biol, 42, pp.e48~e60 (2022)
- Kronenberg F, "Lipoprotein(a)in atherosclerotic cardiovascular disease and aortic stenosis : a European Atherosclerosis Society consensus statement", Eur Heart J, 43, pp.3925~3946 (2022)
- Kumar P, "Lipoprotein(a)level as a risk factor for stroke and its subtype : a systematic review and meta-analysis", Sci Rep, 11, pp.15660~ (2021)
- Díaz-Peromingo JA, "Lipoprotein(a)and lipid profile in patients with atrial fibrillation", Med Sci Monit, 12, pp.CR122~CR125 (2006)
- Tao J, "Low lipoprotein(a)concentration is associated with atrial fibrillation : a large retrospective cohort study", Lipids Health Dis, 21, pp.119~ (2022)
- Naji F, "Lipoprotein(a)and inflammation in patients with atrial fibrillation after electrical cardioversion", J Negat Results Biomed, 10, pp.15~ (2011)
- Mora S, "Paradoxical association of lipoprotein measures with incident atrial fibrillation", Circ Arrhythm Electrophysiol, 7, pp.612~619 (2014)
- Aronis KN, "Associations of lipoprotein(a)levels with incident atrial fibrillation and ischemic stroke : the ARIC(Atherosclerosis Risk in Communities)study", J Am Heart Assoc, 6, pp.e007372~ (2017)
- Li WJ, "The prospective effect of lipoprotein(a)on new-onset atrial fibrillation in patients with chronic heart failure", Int J Clin Exp Med, 9, pp.18316~18323 (2016)
- )and risk for incident atrial fibrillation : multi-ethnic study of atherosclerosis, "Circ Arrhythm Electrophysiol", 2020, e008401~
- Xia J, "Association of Lipoprotein(a)variants with risk of cardiovascular disease : a Mendelian randomization study", Lipids Health Dis, 20, pp.57~ (2021)
- Jiang Q, "Causal effects of plasma lipids on the risk of atrial fibrillation : a multivariable mendelian randomization study", Nutr Metab Cardiovasc Dis, 31, pp.1569~1578 (2021)
- Wang S, "The relationship between lipoprotein(a)and risk of cardiovascular disease : a Mendelian randomization analysis", Eur J Med Res, 27, pp.211~ (2022)
- Mohammadi-Shemirani P, "Elevated lipoprotein(a)and risk of atrial fibrillation : an observational and mendelian randomization study", J Am Coll Cardiol, 79, pp.1579~1590 (2022)
- Arya S, "PRISMA reporting guidelines for meta-analyses and systematic reviews", JAMA Surg, 156, pp.789~790 (2021)
- Sterne JA, "ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions", BMJ, 355, pp.i4919~ (2016)
- Wu N, "Prediction model of new onset atrial fibrillation in patients with acute coronary syndrome", Int J Clin Pract, 2023, pp.3473603~ (2023)
- Salis F, "Frailty and comorbidity burden in atrial fibrillation", Front Public Health, 11, pp.1134453~ (2023)
- Arslan G, "The incidence of atrial fibrillation after on-pump versus off-pump coronary artery bypass grafting", Heart Surg Forum, 24, pp.E645~E650 (2021)
- Kamstrup PR, "Extreme lipoprotein(a)levels and risk of myocardial infarction in the general population : the Copenhagen City Heart Study", Circulation, 117, pp.176~184 (2008)
- Stătescu C, "A systematic review on the risk modulators of myocardial infarction in the"Young"-implications of lipoprotein(a)", Int J Mol Sci, 24, pp.5927~ (2023)
- Lotfi ME, "The role of interleukins in pathogenesis and prognosis of atrial fibrillation", Expert Rev Clin Immunol, 19, pp.585~597 (2023)
- Dzobo KE, "Lipoprotein(a) : an underestimated inflammatory mastermind", Atherosclerosis, 349, pp.101~109 (2022)
- Bouchareb R, "Autotaxin derived from lipoprotein(a)and valve interstitial cells promotes inflammation and mineralization of the aortic valve", Circulation, 132, pp.677~690 (2015)
- Zheng KH, "Lipoprotein(a)and oxidized phospholipids promote valve calcification in patients with aortic stenosis", J Am Coll Cardiol, 73, pp.2150~2162 (2019)
- Tsimikas S, "Ancestry, lipoprotein(a), and cardiovascular risk thresholds : JACC review topic of the week", J Am Coll Cardiol, 80, pp.934~946 (2022)